PATENTSCOPE: PA:ferring

MANUFACTURING OF PHARMACEUTICAL COMPOSITIONS (Fri, 22 Mar 2019)
The present disclosure discloses a process for the continuous manufacture of a liquid pharmaceutical composition, the process comprising providing a mixing unit, feeding a therapeutic agent and a liquid vehicle to the mixing unit, operating the latter thereby mixing the agent and the vehicle into a liquid pharmaceutical composition, discharging the composition into a holding unit.
>> Read More

COMPOSITION FOR CONTROLLED OVARIAN STIMULATION (Fri, 08 Mar 2019)
Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility in patients having high AMH and low bodyweight.
>> Read More

METHOD OF MANUFACTURING A PHARMACEUTICAL COMPOSITION (Fri, 15 Feb 2019)
The present invention relates to crystalline forms of carbetocin, a method of their manufacture, and pharmaceutical compositions thereof.
>> Read More

METHOD OF MANUFACTURING OF OXYTOCIN (Fri, 15 Feb 2019)
A method of manufacturing oxytocin or oxytocin receptor agonist comprising a step of combining an antisolvent with a solution comprising oxytocin or oxytocin receptor agonist so as to precipitate a product oxytocin or a product oxytocin receptor agonist from the solution.
>> Read More

ORAL PHARMACEUTICAL COMPOSITIONS OF CORTICOSTEROIDS (Fri, 26 Oct 2018)
Described herein are oral pharmaceutical compositions of corticosteroids that undergo a sol- gel transition, as well as methods of making such oral pharmaceutical compositions, and therapeutic methods using them. The compositions typically comprise a corticosteroid, a solvent for the corticosteroid and a thermoreversible polymer. The compositions are particularly useful for treating inflammatory conditions of the esophagus, such as eosinophilic esophagitis.
>> Read More

A FAST DISINTEGRATING PHARMACEUTICAL COMPOSITION (Fri, 20 Jul 2018)
The subject invention is directed to a pharmaceutical composition comprising an open matrix network incorporating one or more pharmaceutically active ingredients, wherein the open matrix network comprises maltodextrin and hyaluronic acid or a pharmaceutically acceptable salt thereof.
>> Read More

ANTIMICROBIAL PEPTIDES (Fri, 22 Jun 2018)
This disclosure relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof: Formula (I), in which n, R1, R1', R2, R3, R4, R4', and R5-R14 are defined in the specification. The compounds of formula (I) can be used to treat bacterial infection.
>> Read More

RECTAL FOAM FORMULATIONS (Fri, 22 Jun 2018)
Described herein are pharmaceutical rectal foam formulations, useful, for example, for the rectal administration of therapeutic agents, such as 5-aminosalicylic acid (5-ASA), as well as methods of making such foam formulations, and therapeutic methods using them.
>> Read More

STABILIZED LIQUID FORMULATIONS CONTAINING PICOSULFATE (Fri, 12 Jan 2018)
Stable liquid formulations containing picosulfate and magnesium citrate are provided. The formulations are useful to treat constipation or for the clearance of the bowel prior to X-ray examination, endoscopy or surgery.
>> Read More

ANGIOTENSIN-1-RECEPTOR ANTAGONISTS (Fri, 08 Dec 2017)
In one aspect, this disclosure features compounds of formula (I)or a pharmaceutically acceptable salt thereof: AA1-Arg-Val-AA4-AA5-His-Pro-AA8-OH(I), in which AA1, AA4, AA5, and AA8 are defined in the specification. The compounds of formula (I) can be used to treat hypertension(e.g., hypertension induced by pregnancy), preeclampsia,or a renal disease induced bypregnancy.
>> Read More

ORAL PHARMACEUTICAL COMPOSITIONS OF NICOTINAMIDE (Fri, 27 Oct 2017)
Described herein are pharmaceutical compositions for the oral administration of nicotinamide, or a combination of nicotinamide and mesalazine, as well as methods of making such pharmaceutical compositions, and therapeutic methods for using them. The compositions comprise delayed-immediate release and delayed-extended release formulation of nicotinamide or a combination of nicotinamide and mesalazine.
>> Read More

ORAL PHARMACEUTICAL COMPOSITIONS OF MESALAZINE (Fri, 27 Oct 2017)
Described herein are pharmaceutical compositions for the oral administration of mesalazine, as well as methods of making such pharmaceutical compositions, and therapeutic methods for using them. The compositions comprise delayed-immediate release and delayed- extended release formulation of mesalazine.
>> Read More

STABLE LIQUID GONADOTROPIN FORMULATION (Fri, 01 Sep 2017)
The present invention pertains in general to the field of the stabilization of gonadotropin formulations, in particular liquid formulations of gonadotropins. The stabilization is achieved by a particular combination of excipients, preferably arginine and methionine. In a preferred embodiment, the formulation does not comprise a buffer.
>> Read More

NEW METHODS FOR MAKING BARUSIBAN AND ITS INTERMEDIATES (Fri, 14 Apr 2017)
The present invention relates to new solid phase peptide methods for synthesizing analogues that exhibit oxytocin antagonist activity, specifically Barusiban and its intermediates. Specifically, the present invention relates to a solid phase process for preparing a compound having the formula c[AA1-AA6]-AA7-ol, wherein AA1 is propionic acid, AA2 is preferably D-Trp, AA3 is Ile, AA4 is preferably AlloIle, AA5 is Asn, AA6 is hCy, and AA7 is preferably N-Me-Orn-ol, or a pharmaceutically acceptable salt or solvate thereof.
>> Read More

LIQUID FORMULATIONS CONTAINING PICOSULFATE AND MAGNESIUM CITRATE (Fri, 24 Feb 2017)
Liquid formulations containing picosulfate and magnesium citrate are provided. The formulations are useful to treat constipation or for the clearance of the bowel prior to X-ray examination, endoscopy or surgery.
>> Read More

LACTOBACILLUS RHAMNOSUS BACTERIUM FOR TREATMENT OF E.G. BACTERIAL VAGINOSIS (Fri, 06 Jan 2017)
A novel lactic acid Lactobacillus rhamnosus bacterium suitable for treatment of e.g. bacterial vaginosis.
>> Read More

METHODS OF PURIFICATION AND/OR VIRAL INACTIVATION (Fri, 30 Dec 2016)
Methods of purification and/or viral deactivation of a protein (e.g. glycoprotein) comprising a step of treating the protein (e.g. glycoprotein) with a combination of caprylic acid and ethanol.
>> Read More

METHOD OF PRODUCTION OF GONADOTROPHIN (Fri, 28 Oct 2016)
A host cell characterized in that it comprises integrated into its genome a sequence coding for the a chain of hCG, and use of the host cell to produce recombinant hCG.
>> Read More

COMPOSITION FOR TREATMENT OF INFERTILITY (Fri, 21 Oct 2016)
Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility.
>> Read More

METHODS OF TREATING INFERTILITY (Fri, 02 Sep 2016)
The present invention relates to improved assisted reproductive technology using highly purified menotropin (HP-hMG) to stimulate follicle development in controlled ovarian stimulation, particularly in women at risk of a high ovarian response to controlled ovarian stimulation.
>> Read More